世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

脳腫瘍の診断と治療薬 - 世界市場シェアとランキング、全体売上高と需要予測 2024-2030


Brain Tumor Diagnosis and Therapeutics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

脳腫瘍は手術、放射線療法、化学療法で治療される。本レポートでは主に脳腫瘍診断・治療薬市場に焦点を当てています。 脳腫瘍の診断と治療薬の世界市場は、2023年に2億5,100万米ドルの価値があると推定され、202... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2024年2月16日 US$3,950
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

脳腫瘍は手術、放射線療法、化学療法で治療される。本レポートでは主に脳腫瘍診断・治療薬市場に焦点を当てています。
脳腫瘍の診断と治療薬の世界市場は、2023年に2億5,100万米ドルの価値があると推定され、2024年から2030年の予測期間中のCAGRは9.8%で、2030年までに4億6,857万米ドルの再調整規模になると予測されています。
脳腫瘍診断・治療薬の北米市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に年平均成長率%で、2030年までに100万ドルに達する見込みです。
脳腫瘍診断と治療薬のアジア太平洋市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に%のCAGRで、2030年までに100万ドルに達する見込みです。
脳腫瘍診断と治療薬のヨーロッパ市場は、2023年に100万ドルと評価され、2024年から2030年の予測期間中に年平均成長率%で、2030年までに100万ドルに達する見込みです。
脳腫瘍診断および治療薬の世界的な主要企業には、GEヘルスケア、日立製作所、フィリップスヘルスケア、シーメンス・ヘルスニイヤーズ、株式会社東芝、富士フイルム株式会社、株式会社島津製作所、Merck & Co.、AstraZenecaなどがあります。2023年には、世界の大手5社が売上高で約 %のシェアを占めている。

レポートの範囲
本レポートは、脳腫瘍診断・治療薬の世界市場を包括的に紹介することを目的としており、地域別・国別、タイプ別、用途別の脳腫瘍診断・治療薬の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。
脳腫瘍診断と治療薬の市場規模、推定、予測は、2023年を基準年として、2019年から2030年までの期間の履歴データと予測データを売上高(百万ドル)で提供します。定量的および定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、脳腫瘍診断および治療薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。

市場区分
企業別
GEヘルスケア
日立製作所
フィリップスヘルスケア
シーメンス・ヘルスイニアス
株式会社東芝
富士フイルム株式会社
株式会社島津製作所
メルク社
アストラゼネカ
ブリストル・マイヤー・スクイブ
ノバルティス
ロシュ・ダイアグノスティックス
タイプ別セグメント
MRI
CTスキャン
組織サンプリング
PET-CTスキャン
脳動脈造影
腰椎穿刺
分子検査
脳波検査
用途別セグメント
手術
放射線療法
化学療法
免疫療法
標的療法
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦

各章の概要
第1章:報告書のスコープ、世界の総市場規模を紹介します。本章ではまた、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章 脳腫瘍診断・治療薬メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。
第3章:各種市場セグメントをタイプ別に分析し、各市場セグメントの市場規模や発展可能性を網羅し、読者が各市場セグメントにおけるブルーオーシャン市場を見つけやすくします。
第4章:用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第5章:地域レベルでの脳腫瘍診断と治療薬の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、市場規模を紹介しています。
第6章 国別脳腫瘍診断・治療薬の収益各国・地域のタイプ別、用途別のシグメイトデータを提供しています。
第7章:主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本状況を詳細に紹介。
第8章:産業の上流と下流を含む産業チェーンの分析。
第9章:結論


ページTOPに戻る


目次

1 Market Overview
1.1 Brain Tumor Diagnosis and Therapeutics Product Introduction
1.2 Global Brain Tumor Diagnosis and Therapeutics Market Size Forecast
1.3 Brain Tumor Diagnosis and Therapeutics Market Trends & Drivers
1.3.1 Brain Tumor Diagnosis and Therapeutics Industry Trends
1.3.2 Brain Tumor Diagnosis and Therapeutics Market Drivers & Opportunity
1.3.3 Brain Tumor Diagnosis and Therapeutics Market Challenges
1.3.4 Brain Tumor Diagnosis and Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Brain Tumor Diagnosis and Therapeutics Players Revenue Ranking (2023)
2.2 Global Brain Tumor Diagnosis and Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Brain Tumor Diagnosis and Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Brain Tumor Diagnosis and Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Brain Tumor Diagnosis and Therapeutics
2.6 Brain Tumor Diagnosis and Therapeutics Market Competitive Analysis
2.6.1 Brain Tumor Diagnosis and Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Brain Tumor Diagnosis and Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Brain Tumor Diagnosis and Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 MRI
3.1.2 CT Scan
3.1.3 Tissue Sampling
3.1.4 PET-CT Scan
3.1.5 Cerebral Arteriogram
3.1.6 Lumbar Puncture
3.1.7 Molecular Testing
3.1.8 EEG
3.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type
3.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Surgery
4.1.2 Radiation Therapy
4.1.3 Chemotherapy
4.1.4 Immunotherapy
4.1.5 Targeted Therapy
4.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application
4.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region
5.1.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.2.2 North America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.3.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.5.2 South America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value
6.3 United States
6.3.1 United States Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.3.2 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.4.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.5.2 China Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.6.2 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.9.2 India Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GE Healthcare
7.1.1 GE Healthcare Profile
7.1.2 GE Healthcare Main Business
7.1.3 GE Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.1.4 GE Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 GE Healthcare Recent Developments
7.2 Hitachi
7.2.1 Hitachi Profile
7.2.2 Hitachi Main Business
7.2.3 Hitachi Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.2.4 Hitachi Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Hitachi Recent Developments
7.3 Philips Healthcare
7.3.1 Philips Healthcare Profile
7.3.2 Philips Healthcare Main Business
7.3.3 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.3.4 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Siemens Healthineers Recent Developments
7.4 Siemens Healthineers
7.4.1 Siemens Healthineers Profile
7.4.2 Siemens Healthineers Main Business
7.4.3 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.4.4 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Siemens Healthineers Recent Developments
7.5 Toshiba Corporation
7.5.1 Toshiba Corporation Profile
7.5.2 Toshiba Corporation Main Business
7.5.3 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.5.4 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 Toshiba Corporation Recent Developments
7.6 Fujifilm Corporation
7.6.1 Fujifilm Corporation Profile
7.6.2 Fujifilm Corporation Main Business
7.6.3 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.6.4 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Fujifilm Corporation Recent Developments
7.7 Shimadzu Corporation
7.7.1 Shimadzu Corporation Profile
7.7.2 Shimadzu Corporation Main Business
7.7.3 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.7.4 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Shimadzu Corporation Recent Developments
7.8 Merck & Co.
7.8.1 Merck & Co. Profile
7.8.2 Merck & Co. Main Business
7.8.3 Merck & Co. Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.8.4 Merck & Co. Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Merck & Co. Recent Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Profile
7.9.2 AstraZeneca Main Business
7.9.3 AstraZeneca Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.9.4 AstraZeneca Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 AstraZeneca Recent Developments
7.10 Bristol Myer Squibb
7.10.1 Bristol Myer Squibb Profile
7.10.2 Bristol Myer Squibb Main Business
7.10.3 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.10.4 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Bristol Myer Squibb Recent Developments
7.11 Novartis
7.11.1 Novartis Profile
7.11.2 Novartis Main Business
7.11.3 Novartis Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.11.4 Novartis Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 Novartis Recent Developments
7.12 Roche Diagnostics
7.12.1 Roche Diagnostics Profile
7.12.2 Roche Diagnostics Main Business
7.12.3 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.12.4 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.12.5 Roche Diagnostics Recent Developments
8 Industry Chain Analysis
8.1 Brain Tumor Diagnosis and Therapeutics Industrial Chain
8.2 Brain Tumor Diagnosis and Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Brain Tumor Diagnosis and Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Brain Tumor Diagnosis and Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る


 

Summary

Brain tumors are treated with surgery, radiation therapy and chemotherapy. This report mainly focuses on brain tumor diagnosis and therapeutics market.
The global market for Brain Tumor Diagnosis and Therapeutics was estimated to be worth US$ 2581 million in 2023 and is forecast to a readjusted size of US$ 4685.7 million by 2030 with a CAGR of 9.8% during the forecast period 2024-2030
North American market for Brain Tumor Diagnosis and Therapeutics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Brain Tumor Diagnosis and Therapeutics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Brain Tumor Diagnosis and Therapeutics was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Brain Tumor Diagnosis and Therapeutics include GE Healthcare, Hitachi, Philips Healthcare, Siemens Healthineers, Toshiba Corporation, Fujifilm Corporation, Shimadzu Corporation, Merck & Co. and AstraZeneca, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Brain Tumor Diagnosis and Therapeutics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Brain Tumor Diagnosis and Therapeutics by region & country, by Type, and by Application.
The Brain Tumor Diagnosis and Therapeutics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Brain Tumor Diagnosis and Therapeutics.

Market Segmentation
By Company
GE Healthcare
Hitachi
Philips Healthcare
Siemens Healthineers
Toshiba Corporation
Fujifilm Corporation
Shimadzu Corporation
Merck & Co.
AstraZeneca
Bristol Myer Squibb
Novartis
Roche Diagnostics
Segment by Type:
MRI
CT Scan
Tissue Sampling
PET-CT Scan
Cerebral Arteriogram
Lumbar Puncture
Molecular Testing
EEG
Segment by Application
Surgery
Radiation Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Brain Tumor Diagnosis and Therapeutics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Brain Tumor Diagnosis and Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Brain Tumor Diagnosis and Therapeutics in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Brain Tumor Diagnosis and Therapeutics Product Introduction
1.2 Global Brain Tumor Diagnosis and Therapeutics Market Size Forecast
1.3 Brain Tumor Diagnosis and Therapeutics Market Trends & Drivers
1.3.1 Brain Tumor Diagnosis and Therapeutics Industry Trends
1.3.2 Brain Tumor Diagnosis and Therapeutics Market Drivers & Opportunity
1.3.3 Brain Tumor Diagnosis and Therapeutics Market Challenges
1.3.4 Brain Tumor Diagnosis and Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Brain Tumor Diagnosis and Therapeutics Players Revenue Ranking (2023)
2.2 Global Brain Tumor Diagnosis and Therapeutics Revenue by Company (2019-2024)
2.3 Key Companies Brain Tumor Diagnosis and Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Brain Tumor Diagnosis and Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Brain Tumor Diagnosis and Therapeutics
2.6 Brain Tumor Diagnosis and Therapeutics Market Competitive Analysis
2.6.1 Brain Tumor Diagnosis and Therapeutics Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Brain Tumor Diagnosis and Therapeutics Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Brain Tumor Diagnosis and Therapeutics as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 MRI
3.1.2 CT Scan
3.1.3 Tissue Sampling
3.1.4 PET-CT Scan
3.1.5 Cerebral Arteriogram
3.1.6 Lumbar Puncture
3.1.7 Molecular Testing
3.1.8 EEG
3.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type
3.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (2019-2030)
3.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Surgery
4.1.2 Radiation Therapy
4.1.3 Chemotherapy
4.1.4 Immunotherapy
4.1.5 Targeted Therapy
4.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application
4.2.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (2019-2030)
4.2.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region
5.1.1 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2019-2024)
5.1.3 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (2025-2030)
5.1.4 Global Brain Tumor Diagnosis and Therapeutics Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.2.2 North America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.3.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.4.2 Asia Pacific Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.5.2 South America Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
5.6.2 Middle East & Africa Brain Tumor Diagnosis and Therapeutics Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Brain Tumor Diagnosis and Therapeutics Sales Value
6.3 United States
6.3.1 United States Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.3.2 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.4.2 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.5.2 China Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.5.3 China Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.6.2 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.7.2 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.8.2 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Brain Tumor Diagnosis and Therapeutics Sales Value, 2019-2030
6.9.2 India Brain Tumor Diagnosis and Therapeutics Sales Value by Type (%), 2023 VS 2030
6.9.3 India Brain Tumor Diagnosis and Therapeutics Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 GE Healthcare
7.1.1 GE Healthcare Profile
7.1.2 GE Healthcare Main Business
7.1.3 GE Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.1.4 GE Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.1.5 GE Healthcare Recent Developments
7.2 Hitachi
7.2.1 Hitachi Profile
7.2.2 Hitachi Main Business
7.2.3 Hitachi Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.2.4 Hitachi Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.2.5 Hitachi Recent Developments
7.3 Philips Healthcare
7.3.1 Philips Healthcare Profile
7.3.2 Philips Healthcare Main Business
7.3.3 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.3.4 Philips Healthcare Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.3.5 Siemens Healthineers Recent Developments
7.4 Siemens Healthineers
7.4.1 Siemens Healthineers Profile
7.4.2 Siemens Healthineers Main Business
7.4.3 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.4.4 Siemens Healthineers Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.4.5 Siemens Healthineers Recent Developments
7.5 Toshiba Corporation
7.5.1 Toshiba Corporation Profile
7.5.2 Toshiba Corporation Main Business
7.5.3 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.5.4 Toshiba Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.5.5 Toshiba Corporation Recent Developments
7.6 Fujifilm Corporation
7.6.1 Fujifilm Corporation Profile
7.6.2 Fujifilm Corporation Main Business
7.6.3 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.6.4 Fujifilm Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.6.5 Fujifilm Corporation Recent Developments
7.7 Shimadzu Corporation
7.7.1 Shimadzu Corporation Profile
7.7.2 Shimadzu Corporation Main Business
7.7.3 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.7.4 Shimadzu Corporation Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.7.5 Shimadzu Corporation Recent Developments
7.8 Merck & Co.
7.8.1 Merck & Co. Profile
7.8.2 Merck & Co. Main Business
7.8.3 Merck & Co. Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.8.4 Merck & Co. Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.8.5 Merck & Co. Recent Developments
7.9 AstraZeneca
7.9.1 AstraZeneca Profile
7.9.2 AstraZeneca Main Business
7.9.3 AstraZeneca Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.9.4 AstraZeneca Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.9.5 AstraZeneca Recent Developments
7.10 Bristol Myer Squibb
7.10.1 Bristol Myer Squibb Profile
7.10.2 Bristol Myer Squibb Main Business
7.10.3 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.10.4 Bristol Myer Squibb Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.10.5 Bristol Myer Squibb Recent Developments
7.11 Novartis
7.11.1 Novartis Profile
7.11.2 Novartis Main Business
7.11.3 Novartis Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.11.4 Novartis Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.11.5 Novartis Recent Developments
7.12 Roche Diagnostics
7.12.1 Roche Diagnostics Profile
7.12.2 Roche Diagnostics Main Business
7.12.3 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Products, Services and Solutions
7.12.4 Roche Diagnostics Brain Tumor Diagnosis and Therapeutics Revenue (US$ Million) & (2019-2024)
7.12.5 Roche Diagnostics Recent Developments
8 Industry Chain Analysis
8.1 Brain Tumor Diagnosis and Therapeutics Industrial Chain
8.2 Brain Tumor Diagnosis and Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Brain Tumor Diagnosis and Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Brain Tumor Diagnosis and Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

  • 本レポートと同分野の最新刊レポートはありません。

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/07/12 10:27

160.11 円

174.44 円

209.47 円

ページTOPに戻る